We are honoured to be featured as a case study in the recent British Private Equity & Venture Capital Association (BVCA) Report on Investment Activity in 2023. The significant progress we have made would not have been possible without the invaluable support of our venture capital partner, Mercia Asset Management. As we continue our journey and look to expand in to Europe, we look forward to developing and launching innovative medicines that address the needs of both patients and the NHS. We extend our sincere thanks to Mercia and the wider venture capital community for enabling the growth and success of our business and others like us.

Please take a look at the BVCA report.